Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
VNDA's Cash to Debt is ranked higher than
91% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. VNDA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VNDA' s 10-Year Cash to Debt Range
Min: 209.57  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.67
VNDA's Equity to Asset is ranked lower than
52% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. VNDA: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
VNDA' s 10-Year Equity to Asset Range
Min: 0.01  Med: 0.16 Max: 0.94
Current: 0.67
0.01
0.94
Interest Coverage No Debt
VNDA's Interest Coverage is ranked higher than
84% of the 381 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VNDA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VNDA' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 5
Z-Score: 4.02
M-Score: 2.14
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 65.71
VNDA's Operating margin (%) is ranked higher than
97% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. VNDA: 65.71 )
Ranked among companies with meaningful Operating margin (%) only.
VNDA' s 10-Year Operating margin (%) Range
Min: -28023.53  Med: -62.58 Max: 40
Current: 65.71
-28023.53
40
Net-margin (%) 65.95
VNDA's Net-margin (%) is ranked higher than
97% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. VNDA: 65.95 )
Ranked among companies with meaningful Net-margin (%) only.
VNDA' s 10-Year Net-margin (%) Range
Min: -27864.71  Med: -62.15 Max: 40.25
Current: 65.95
-27864.71
40.25
ROE (%) 56.65
VNDA's ROE (%) is ranked higher than
97% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. VNDA: 56.65 )
Ranked among companies with meaningful ROE (%) only.
VNDA' s 10-Year ROE (%) Range
Min: -246.18  Med: -91.29 Max: 23.67
Current: 56.65
-246.18
23.67
ROA (%) 34.02
VNDA's ROA (%) is ranked higher than
98% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. VNDA: 34.02 )
Ranked among companies with meaningful ROA (%) only.
VNDA' s 10-Year ROA (%) Range
Min: -176.39  Med: -21.71 Max: 12.81
Current: 34.02
-176.39
12.81
ROC (Joel Greenblatt) (%) 1453.89
VNDA's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. VNDA: 1453.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VNDA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4620.09  Med: -2021.63 Max: 784.55
Current: 1453.89
-4620.09
784.55
Revenue Growth (3Y)(%) 7.30
VNDA's Revenue Growth (3Y)(%) is ranked higher than
59% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. VNDA: 7.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VNDA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: 89.7
Current: 7.3
0
89.7
» VNDA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

VNDA Guru Trades in Q3 2014

John Paulson 3,250,000 sh (+1.56%)
» More
Q4 2014

VNDA Guru Trades in Q4 2014

John Paulson 3,625,000 sh (+11.54%)
John Paulson 3,625,000 sh (unchged)
» More
Q1 2015

VNDA Guru Trades in Q1 2015

Paul Tudor Jones 25,000 sh (New)
Jim Simons 195,100 sh (New)
John Paulson 3,950,000 sh (+8.97%)
» More
Q2 2015

VNDA Guru Trades in Q2 2015

Steven Cohen 96,500 sh (New)
Jim Simons Sold Out
John Paulson 3,946,500 sh (-0.09%)
Paul Tudor Jones 21,194 sh (-15.22%)
» More
» Details

Insider Trades

Latest Guru Trades with VNDA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 10.60
VNDA's P/E(ttm) is ranked higher than
91% of the 220 Companies
in the Global Biotechnology industry.

( Industry Median: 33.70 vs. VNDA: 10.60 )
Ranked among companies with meaningful P/E(ttm) only.
VNDA' s 10-Year P/E(ttm) Range
Min: 9.79  Med: 32.80 Max: 217.54
Current: 10.6
9.79
217.54
Forward P/E 121.95
VNDA's Forward P/E is ranked lower than
88% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 23.42 vs. VNDA: 121.95 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 10.60
VNDA's PE(NRI) is ranked higher than
92% of the 216 Companies
in the Global Biotechnology industry.

( Industry Median: 33.30 vs. VNDA: 10.60 )
Ranked among companies with meaningful PE(NRI) only.
VNDA' s 10-Year PE(NRI) Range
Min: 9.78  Med: 30.96 Max: 214.43
Current: 10.6
9.78
214.43
P/B 3.32
VNDA's P/B is ranked higher than
59% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. VNDA: 3.32 )
Ranked among companies with meaningful P/B only.
VNDA' s 10-Year P/B Range
Min: 2.53  Med: 6.36 Max: 540.33
Current: 3.32
2.53
540.33
P/S 6.06
VNDA's P/S is ranked higher than
67% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. VNDA: 6.06 )
Ranked among companies with meaningful P/S only.
VNDA' s 10-Year P/S Range
Min: 2.62  Med: 6.85 Max: 69.06
Current: 6.06
2.62
69.06
EV-to-EBIT 6.85
VNDA's EV-to-EBIT is ranked higher than
87% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 26.88 vs. VNDA: 6.85 )
Ranked among companies with meaningful EV-to-EBIT only.
VNDA' s 10-Year EV-to-EBIT Range
Min: -1288.6  Med: 0.55 Max: 578.2
Current: 6.85
-1288.6
578.2
Current Ratio 3.86
VNDA's Current Ratio is ranked lower than
53% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. VNDA: 3.86 )
Ranked among companies with meaningful Current Ratio only.
VNDA' s 10-Year Current Ratio Range
Min: 1.67  Med: 4.94 Max: 18.62
Current: 3.86
1.67
18.62
Quick Ratio 3.75
VNDA's Quick Ratio is ranked lower than
51% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. VNDA: 3.75 )
Ranked among companies with meaningful Quick Ratio only.
VNDA' s 10-Year Quick Ratio Range
Min: 1.64  Med: 4.94 Max: 18.62
Current: 3.75
1.64
18.62
Days Inventory 104.74
VNDA's Days Inventory is ranked higher than
57% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. VNDA: 104.74 )
Ranked among companies with meaningful Days Inventory only.
VNDA' s 10-Year Days Inventory Range
Min: 80.64  Med: 190.04 Max: 596.04
Current: 104.74
80.64
596.04
Days Sales Outstanding 72.28
VNDA's Days Sales Outstanding is ranked lower than
56% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. VNDA: 72.28 )
Ranked among companies with meaningful Days Sales Outstanding only.
VNDA' s 10-Year Days Sales Outstanding Range
Min: 5.22  Med: 20.39 Max: 253.93
Current: 72.28
5.22
253.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.86
VNDA's Price/Net Cash is ranked higher than
54% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 7.88 vs. VNDA: 6.86 )
Ranked among companies with meaningful Price/Net Cash only.
VNDA' s 10-Year Price/Net Cash Range
Min: 0.31  Med: 8.25 Max: 1625
Current: 6.86
0.31
1625
Price/Net Current Asset Value 4.97
VNDA's Price/Net Current Asset Value is ranked higher than
61% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 6.84 vs. VNDA: 4.97 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VNDA' s 10-Year Price/Net Current Asset Value Range
Min: 0.3  Med: 8.25 Max: 185
Current: 4.97
0.3
185
Price/Tangible Book 4.75
VNDA's Price/Tangible Book is ranked higher than
54% of the 690 Companies
in the Global Biotechnology industry.

( Industry Median: 5.33 vs. VNDA: 4.75 )
Ranked among companies with meaningful Price/Tangible Book only.
VNDA' s 10-Year Price/Tangible Book Range
Min: 0.29  Med: 6.65 Max: 392
Current: 4.75
0.29
392
Price/Median PS Value 0.89
VNDA's Price/Median PS Value is ranked higher than
62% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. VNDA: 0.89 )
Ranked among companies with meaningful Price/Median PS Value only.
VNDA' s 10-Year Price/Median PS Value Range
Min: 0.46  Med: 1.00 Max: 9.62
Current: 0.89
0.46
9.62
Price/Graham Number 1.41
VNDA's Price/Graham Number is ranked higher than
83% of the 173 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. VNDA: 1.41 )
Ranked among companies with meaningful Price/Graham Number only.
VNDA' s 10-Year Price/Graham Number Range
Min: 1.32  Med: 2.71 Max: 3.93
Current: 1.41
1.32
3.93
Earnings Yield (Greenblatt) (%) 14.71
VNDA's Earnings Yield (Greenblatt) (%) is ranked higher than
96% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. VNDA: 14.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VNDA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.2  Med: 42.65 Max: 3521.3
Current: 14.71
0.2
3521.3

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 113 162 224 269
EPS($) -0.49 0.10 1.72 2.56
EPS without NRI($) -0.49 0.10 1.72 2.56

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VM4.Germany,
Vanda Pharmaceuticals Inc was incorporated in Delaware in 2002 and began operations in March 2003. The Company is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders. It operates in one business segment which is the development and commercialization of pharmaceutical products. Its product portfolio includes: HETLIOZ, a product for the treatment of Non-24-Hour Sleep-Wake Disorder, which was approved by the U.S. FDA in January 2014; Fanapt, a product for the treatment of schizophrenia, the oral formulation of which is currently being marketed and sold in the U.S. by Novartis Pharma AG; and VLY-686, a small molecule neurokinin-1 receptor antagonist. The Company utilizes a virtual supply manufacturing and distribution chain in which it does not have its own facilities to manufacture commercial or clinical trial supplies of drugs and does not have its own distribution facilities.
» More Articles for VNDA

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Walker & Dunlop, Arista Networks, Vanda Pharmaceuticals, and Synopsys May 31 2015 
John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
Best Performing Gurus of Past Six Months are John Paulson, First Eagle and Michael Price Jun 11 2013 
comment on VNDA Nov 12 2012 
Vanda: This Company Has Great Assets But No Profits Jan 21 2012 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
$VNDA New study started: Oct 15 2010 
Hourly trend UP Aug 11 2010 
Vanda Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
upgraded to BUY Jul 07 2010 

More From Other Websites
Vanda Pharmaceuticals, Inc. Earnings Q2, 2015 Aug 26 2015
Why Vanda Pharmaceuticals (VNDA) Could Be a Potential Winner Aug 20 2015
Is Volatility in Asian Markets Here to Stay? Aug 19 2015
What's Driving the Global Markets? Aug 18 2015
Vanda Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference Aug 10 2015
VANDA PHARMACEUTICALS INC. Financials Aug 07 2015
HETLIOZ® (tasimelteon) Phase III SET and RESET Trial Results Published in The Lancet Aug 05 2015
10-Q for Vanda Pharmaceuticals, Inc. Aug 03 2015
Vanda Announces Listing of Four New Fanapt® Patents in the FDA Orange Book Aug 03 2015
Vanda Pharmaceuticals (VNDA) Jumps: Stock Moves Up 8.4% - Tale of the Tape Jul 31 2015
VANDA PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Jul 31 2015
Edited Transcript of VNDA earnings conference call or presentation 29-Jul-15 8:30pm GMT Jul 29 2015
Vanda reports 2Q loss Jul 29 2015
Vanda reports 2Q loss Jul 29 2015
Vanda Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Jul 29 2015
VANDA PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 29 2015
Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results Jul 29 2015
Q2 2015 Vanda Pharmaceuticals Inc Earnings Release - After Market Close Jul 29 2015
Vanda Pharmaceuticals to Announce Second Quarter 2015 Financial Results on July 29, 2015 Jul 09 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK